Why the pharmaceutical industry’s future hinges on translating science into business
By Professor Dato Dr Ahmad Ibrahim
A recent paper argues that the pharmaceutical industry is currently facing a paradox that threatens its very business model. We are producing more science than ever, yet the pipeline to the patient is clogged with economic friction, ethical quagmires, and a fundamental disconnect between the lab bench and the balance sheet. The core argument of the study—that “Scientific Business Research” (SBR) is the essential bridge for survival—is a wake-up call. We have spent the last three decades assuming that the explosion in biotechnology and genomics would automatically translate into a golden age of therapeutics. Instead, we are witnessing a landscape defined by soaring R&D costs, pricing scandals, and a looming patent cliff that has left the industry scrambling.
A striking finding is the widening gap between scientific discovery and commercial viability. The industry is shifting from the blockbuster model—where a single drug like Lipitor could prop up an entire corporation—towards niche, specialized therapies, particularly in oncology and rare diseases. While this is a win for personalized medicine, it is a logistical nightmare for business operations. The authors point out that this fragmentation requires a new kind of business leadership: leaders who don’t just understand EBITDA but can actually parse the clinical significance of biomarker data.
Many see a crisis of translation. Venture capital is flushed with cash for early-stage biotech startups, but the “valley of death”—the gap between early research and late-stage clinical trials—is widening. The authors emphasis on SBR suggests that this gap exists not because the science is bad, but because the business architecture surrounding it is archaic. We are trying to commercialize gene therapies with a supply chain and reimbursement model designed for mass-market pills.
The elephant in the room is public trust. The paper notes that the industry’s financial sustainability is increasingly tied to its social license to operate. The authors imply what many industry insiders are too afraid to say out loud: the era of opaque pricing and aggressive marketing tactics is ending, not because of altruism, but because it has become economically unsustainable.
The concept of “Scientific Business Research” is fascinating because it merges two worlds that are often kept at arm’s length. Traditionally, “Medical Affairs” handled the science, and “Commercial” handled the business. When these two functions operate in silos, the industry loses its ability to articulate value. This played out during the COVID-19 pandemic. The companies with the highest reputational capital were not necessarily the ones with the most effective vaccines, but the ones that were able to use scientific business research to navigate public policy, manufacturing scalability, and equitable distribution simultaneously.
Perhaps the most forward-looking section of the paper deals with digital transformation. The next great frontier for the pharmaceutical industry is not a molecule, but data. Real-world evidence, artificial intelligence in drug discovery, and digital therapeutics are no longer futuristic concepts; they are the current battleground. The traditional pharma business model is built on exclusivity—patents, trade secrets, and market control. But the future of SBR requires interoperability. If a pharmaceutical company wants to prove that its drug saves money for the healthcare system, it needs to share data with payers and providers. If it wants to use AI to shorten development timelines, it needs to break down data silos within its own organization. The winners of the next decade will be those who treat data with the same rigor they treat a New Chemical Entity (NCE).
The paper touches on a trend that has exploded: geopolitical fragmentation, citing the challenges of global supply chains and regulatory divergence. Many see the “de-globalization” of pharma. The EU is pushing for sovereignty in Active Pharmaceutical Ingredient (API) manufacturing, while the U.S. is leveraging the Inflation Reduction Act to dictate pricing. In this environment, “Scientific Business Research” becomes a tool for geopolitical navigation. Understanding where to manufacture, how to price across borders, and how to navigate the regulatory maze in Brussels versus Washington is now a core scientific competency. A great molecule is no longer enough. You need a great business model to deliver it.
The pharmaceutical industry is at an inflection point. The challenges of pricing pressure, digital disruption, and waning trust are not peripheral issues for the communications department; they are existential threats that require scientific rigor. The future belongs to those who can treat business strategy not as a secondary consideration, but as a scientific discipline in its own right. If the industry fails to bridge the gap between the lab and the ledger, we won’t just see a market correction—we will see a deceleration in the innovation that millions of patients are waiting for.
The author is affiliated with the Tan Sri Omar Centre for STI Policy Studies at UCSI University and is an Adjunct Professor at the Ungku Aziz Centre for Development Studies, Universiti Malaya. He can be reached at ahmadibrahim@ucsiuniversity.edu.my.